US Stock Insider Trading | Ingevity disclosed 5 insider transactions on March 2

K-LinePoet

2026-03-11 16:14:48

Abstract generation in progress

On March 2, 2026, Ingevity (NGVT) disclosed five insider transactions. Executive Hall Mary Dean sold 873 shares on February 26, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 2, 2026	Executive	PLATT PHILLIP JOHN	February 26, 2026	Sell	108	70.52	7,616.16
March 2, 2026	Executive	White Richard Allen JR	February 26, 2026	Sell	430	70.52	30,300.00
March 2, 2026	Executive	Fisher Ryan C.	February 26, 2026	Sell	94	70.52	6,628.88
March 2, 2026	Executive	Clontz Clarence Reid Jr.	February 26, 2026	Sell	69	70.52	4,865.88
March 2, 2026	Executive	Hall Mary Dean	February 26, 2026	Sell	873	70.52	61,600.00
January 6, 2026	Director	Segal Francis David, WILLIS J KEVIN	January 2, 2026	Buy	875	60.09	52,600.00
October 6, 2025	Director	FERNANDEZ-MORENO LUIS M	October 2, 2025	Sell	6,004	56.31	338,100.00
October 2, 2025	Director	Segal Francis David, WILLIS J KEVIN	October 1, 2025	Buy	920	54.44	50,100.00
July 9, 2025	Executive	Fisher Ryan C.	July 7, 2025	Sell	169	45.34	7,662.46
July 3, 2025	Director	Segal Francis David, WILLIS J KEVIN	July 1, 2025	Buy	1,127	44.40	50,000.00

[Company Profile]

Ingevity Corporation was incorporated in Delaware on March 27, 2015. Ingevity is a global leading manufacturer of specialty chemicals and high-performance carbon materials. The company provides innovative solutions through proprietary formulation products to meet the unique and demanding requirements of its customers. With deep technical expertise and experience, flexible manufacturing, unique chemistry, global influence, and a focus on innovation and application development, Ingevity helps its customers enhance their products and competitive position in the markets they serve.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.